Losoxantrone (BioDeep_00000180535)

   

human metabolite blood metabolite


代谢物信息卡片


6-hydroxy-14-{2-[(2-hydroxyethyl)amino]ethyl}-10-({2-[(2-hydroxyethyl)amino]ethyl}amino)-14,15-diazatetracyclo[7.6.1.0^{2,7}.0^{13,16}]hexadeca-1(15),2(7),3,5,9,11,13(16)-heptaen-8-one

化学式: C22H27N5O4 (425.20629420000006)
中文名称: 洛索蒽醌
谱图信息: 最多检出来源 Homo sapiens(blood) 85.71%

分子结构信息

SMILES: C1=CC2=C(C(=C1)O)C(=O)C3=C(C=CC4=C3C2=NN4CCNCCO)NCCNCCO
InChI: InChI=1S/C22H27N5O4/c28-12-9-23-6-7-25-15-4-5-16-20-19(15)22(31)18-14(2-1-3-17(18)30)21(20)26-27(16)11-8-24-10-13-29/h1-5,23-25,28-30H,6-13H2

描述信息

C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent
D000970 - Antineoplastic Agents

同义名列表

7 个代谢物同义名

6-hydroxy-14-{2-[(2-hydroxyethyl)amino]ethyl}-10-({2-[(2-hydroxyethyl)amino]ethyl}amino)-14,15-diazatetracyclo[7.6.1.0^{2,7}.0^{13,16}]hexadeca-1(15),2(7),3,5,9,11,13(16)-heptaen-8-one; 7-Hydroxy-2(2-((2-hydroxyethyl) amino) ethyl)5-(2-((2-hydroxyethyl)amino)ethyl)amino anthra(1,9-CD)pyrazole-6(2H)-one; Anthrapyrazolone; Losoxantrone; Biantrazole; DUP-941; DuP 941



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • A S Joshi, H J Pieniaszek, E E Vokes, N J Vogelzang, A F Davidson, L E Richards, M F Chai, M Finizio, M J Ratain. Elimination pathways of [14C]losoxantrone in four cancer patients. Drug metabolism and disposition: the biological fate of chemicals. 2001 Feb; 29(2):96-9. doi: NULL. [PMID: 11159796]
  • S D Huan, R B Natale, D J Stewart, G P Sartiano, P J Stella, J D Roberts, A L Symes, M Finizio. A multicenter phase II trial of losoxantrone (DuP-941) in hormone-refractory metastatic prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000 Apr; 6(4):1333-6. doi: NULL. [PMID: 10778959]
  • E H Herman, J Zhang, B B Hasinoff, K T Tran, D P Chadwick, J R Clark, V J Ferrans. Comparison of the chronic toxicity of piroxantrone, losoxantrone and doxorubicin in spontaneously hypertensive rats. Toxicology. 1998 Jun; 128(1):35-52. doi: 10.1016/s0300-483x(98)00049-3. [PMID: 9704904]
  • D I Jodrell, L S Murray, J Hawtof, M A Graham, M J Egorin. A comparison of methods for limited-sampling strategy design using data from a phase I trial of the anthrapyrazole DuP-941. Cancer chemotherapy and pharmacology. 1996; 37(4):356-62. doi: 10.1007/s002800050397. [PMID: 8548882]
  • L E Richards, J H Sun. Identification of two regioisomeric monocarboxylic acid metabolites of losoxantrone (DuP 941; Biantrazole) excreted in human urine. Drug metabolism and disposition: the biological fate of chemicals. 1995 May; 23(5):600-2. doi: NULL. [PMID: 7587938]
  • B Proksch, J Blanz, K P Zeller, G Ehninger. Detection and separation of the anthrapyrazole CI-941 and its metabolites in serum and urine by high-performance liquid chromatography. Journal of chromatography. B, Biomedical applications. 1994 Aug; 658(2):349-53. doi: 10.1016/0378-4347(94)00235-5. [PMID: 7820263]
  • J Blanz, U Renner, K Schmeer, G Ehninger, K P Zeller. Detection and identification of human urinary metabolites of biantrazole (CI-941). Drug metabolism and disposition: the biological fate of chemicals. 1993 Sep; 21(5):955-61. doi: NULL. [PMID: 7902262]
  • M A Graham, D R Newell, B J Foster, L A Gumbrell, K E Jenns, A H Calvert. Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme. Cancer research. 1992 Feb; 52(3):603-9. doi: NULL. [PMID: 1732048]
  • M A Graham, D R Newell, A H Calvert. Determination of the anthrapyrazole anticancer drug CI-941 in plasma and urine by solid-phase extraction and high-performance liquid chromatography. Journal of chromatography. 1989 Jun; 491(1):253-61. doi: 10.1016/s0378-4347(00)82841-8. [PMID: 2793977]
  • M A Graham, D R Newell, B J Foster, A H Calvert. The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients. Cancer chemotherapy and pharmacology. 1989; 23(1):8-14. doi: 10.1007/bf00258450. [PMID: 2909292]
  • M A Graham, D R Newell, J Butler, B Hoey, L H Patterson. The effect of the anthrapyrazole antitumour agent CI941 on rat liver microsome and cytochrome P-450 reductase mediated free radical processes. Inhibition of doxorubicin activation in vitro. Biochemical pharmacology. 1987 Oct; 36(20):3345-51. doi: 10.1016/0006-2952(87)90309-1. [PMID: 2823819]
  • P Frank, R F Novak. Effects of anthrapyrazole antineoplastic agents on lipid peroxidation. Biochemical and biophysical research communications. 1986 Nov; 140(3):797-807. doi: 10.1016/0006-291x(86)90704-7. [PMID: 3778486]